New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
The US Senate Committee on Health, Education, Labor and Pensions has approved President Donald Trump’s nomination for Stephen Hahn to serve as the new commissioner of the Food and Drug Administration.
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Barnes & Thornburg has recruited a new life sciences patent group from the IP boutique Brinks, Gilson & Lione.
The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Genus Lifesciences is suing pharmaceutical company Mallinckrodt for misusing trade secrets related to a cocaine hydrochloride formulation.
California-based Bio-Rad Laboratories has obtained an injunction from a German court in its long-running dispute with US biotechnology company 10x Genomics.
China has added 70 medicines to its national medical insurance catalogue, which will reduce the cost of the drugs by more than 60% on average, the National Healthcare Security Administration has said.
Japanese pharmaceutical conglomerate Asahi Kasei has announced it will acquire Danish company Veloxis Pharmaceuticals for $1.3 billion.
Amgen and Coherus Biosciences have settled a patent infringement dispute, after Coherus claimed that Amgen was infringing three of its patents.